Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Consolidated Net Income (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Consolidated Net Income for 11 consecutive years, with -$90.4 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income changed N/A to -$90.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$139.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$153.9 million for FY2025, 293.67% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$90.4 million at Crescent Biopharma, down from -$24.6 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$2.3 million in Q1 2025, with the low at -$90.4 million in Q4 2025.
  • Average Consolidated Net Income over 5 years is -$16.3 million, with a median of -$10.7 million recorded in 2024.
  • Peak annual rise in Consolidated Net Income hit 78.17% in 2025, while the deepest fall reached 835.27% in 2025.
  • Over 5 years, Consolidated Net Income stood at -$17.4 million in 2021, then soared by 41.2% to -$10.2 million in 2022, then increased by 11.38% to -$9.1 million in 2023, then surged by 71.02% to -$2.6 million in 2024, then crashed by 3335.84% to -$90.4 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$90.4 million, -$24.6 million, and -$21.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.